Helsinn has a long-term commitment to bring its core values of quality, integrity and respect to China, offering innovative and high-quality pharmaceutical products and improving the lives of Chinese cancer patients.
Helsinn has been present in Beijing, China since 2012, first with a Representative Office to coordinate clinical and regulatory activities. Subsequently, in 2017, Helsinn Pharmaceuticals (Beijing) Co. Ltd., was established and the Shanghai branch was opened, providing Helsinn with the platform to pursue Shanghai based commercial activities. Currently, several of our cancer supportive care products are under registration with the China National Medical Products Administration (NMPA).
In August 2019, NMPA approved Akynzeo® capsule (300 mg netupitant/0.5 mg palonosetron) for the treatment of chemotherapy-induced nausea and vomiting (CINV). This follows NMPA’s approval of Aloxi® IV (palonosetron HCI), a world-leading CINV anti-emesis product, in November 2018. More product approvals by NMPA are expected in 2020 and beyond. Helsinn is expanding its presence in China, with a Helsinn commercial organization focused on Shanghai, and preparing for the launch of future products. Collaborating with our partners, Helsinn aims to grow steadily and become a leading player in cancer care in China.